Compare Crispr Therapeutics AG (CRSP) vs SoFi Technologies Inc (SOFI) Price & Performance

CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.

The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.

SoFi Technologies (SOFI) trades at $17.82, down 1.66% on the day, with a bullish technical signal from moving averages despite a neutral RSI. The company reported strong Q2 2026 earnings, beating EPS estimates with 40% year-over-year adjusted net revenue growth and record loan originations. Revenue guidance for 2026 was raised to $4.75-$4.85 billion. The stock's valuation shows a P/E of 36.69 and P/S of 5.6, reflecting growth expectations. Analyst consensus is a 'Buy' with a $19.50 price target, though institutional sentiment is mixed with recent position adjustments.

The outlook for SOFI is positive, driven by robust member growth, cross-selling success, and expanding fee-based revenue. Key risks include dependence on interest rate trends, competitive pressures in digital banking, and execution challenges in scaling the technology platform. The stock presents an opportunity for growth investors, but volatility may persist amid macroeconomic uncertainties and investor sensitivity to guidance updates.